| The genomic landscape of endocrine-resistant advanced breast cancers P Razavi, MT Chang, G Xu, C Bandlamudi, DS Ross, N Vasan, Y Cai, ... Cancer cell 34 (3), 427-438. e6, 2018 | 820 | 2018 |
| Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade W Abida, ML Cheng, J Armenia, S Middha, KA Autio, HA Vargas, ... JAMA oncology 5 (4), 471-478, 2019 | 560 | 2019 |
| Tumour lineage shapes BRCA-mediated phenotypes P Jonsson, C Bandlamudi, ML Cheng, P Srinivasan, SS Chavan, ... Nature 571 (7766), 576-579, 2019 | 347 | 2019 |
| Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions ML Cheng, E Pectasides, GJ Hanna, HA Parsons, AD Choudhury, ... CA: A Cancer Journal for Clinicians, 2020 | 144 | 2020 |
| Impact of DNA damage response and repair (DDR) gene mutations on efficacy of PD-(L) 1 immune checkpoint inhibition in non-small cell lung cancer B Ricciuti, G Recondo, LF Spurr, YY Li, G Lamberti, D Venkatraman, ... Clinical Cancer Research, 2020 | 116 | 2020 |
| Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC) B Ricciuti, G Jones, M Severgnini, JV Alessi, G Recondo, M Lawrence, ... Journal for immunotherapy of cancer 9 (3), 2021 | 99 | 2021 |
| Effects of RANKL-targeted therapy in immunity and cancer ML Cheng, L Fong Frontiers in oncology 3, 329, 2014 | 91 | 2014 |
| The incidence of oesophageal cancer in Eastern Africa: identification of a new geographic hot spot? ML Cheng, L Zhang, M Borok, E Chokunonga, C Dzamamala, A Korir, ... Cancer epidemiology 39 (2), 143-149, 2015 | 75 | 2015 |
| SMARCA4 and other SWItch/Sucrose nonfermentable family genomic alterations in NSCLC: clinicopathologic characteristics and outcomes to immune checkpoint inhibition JV Alessi, B Ricciuti, LF Spurr, H Gupta, YY Li, C Glass, M Nishino, ... Journal of Thoracic Oncology 16 (7), 1176-1187, 2021 | 71 | 2021 |
| Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation A Sacher, P LoRusso, MR Patel, WH Miller Jr, E Garralda, MD Forster, ... New England Journal of Medicine 389 (8), 710-721, 2023 | 66 | 2023 |
| Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC). JK Rotow, DB Costa, CP Paweletz, MM Awad, P Marcoux, D Rangachari, ... Journal of Clinical Oncology 38 (15_suppl), 9507-9507, 2020 | 37 | 2020 |
| Clinical tumour sequencing for precision oncology: time for a universal strategy ML Cheng, MF Berger, DM Hyman, DB Solit Nature Reviews Cancer 18 (9), 527-528, 2018 | 37 | 2018 |
| Abiraterone acetate for the treatment of prostate cancer CJ Ryan, ML Cheng Expert opinion on pharmacotherapy 14 (1), 91-96, 2013 | 35 | 2013 |
| Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients DWY Tsui, ML Cheng, M Shady, JL Yang, D Stephens, H Won, ... Genome medicine 13 (1), 1-15, 2021 | 29 | 2021 |
| Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas JM Sands, T Nguyen, P Shivdasani, AG Sacher, ML Cheng, RS Alden, ... Lung Cancer 140, 35-41, 2020 | 29 | 2020 |
| Report of the first international symposium on NUT carcinoma CA French, ML Cheng, GJ Hanna, SG DuBois, NG Chau, CL Hann, ... Clinical Cancer Research 28 (12), 2493-2505, 2022 | 27 | 2022 |
| Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab MA Postow, SD Chasalow, D Kuk, KS Panageas, ML Cheng, J Yuan, ... Melanoma Research 30 (1), 71-75, 2020 | 24 | 2020 |
| OA03. 04 phase IA study to evaluate GDC-6036 monotherapy in patients with non-small cell lung cancer (NSCLC) with KRAS G12C mutation A Sacher, MR Patel, WH Miller, J Desai, E Garralda, S Bowyer, TW Kim, ... Journal of Thoracic Oncology 17 (9), S8-S9, 2022 | 22 | 2022 |
| Does TMB impact the effectiveness of TKIs in EGFR-mutant NSCLC? ML Cheng, GR Oxnard Clinical Cancer Research 25 (3), 899-900, 2019 | 20 | 2019 |
| Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC ML Cheng, CJ Lau, MSD Milan, JG Supplee, JW Riess, PA Bradbury, ... JCO Precision Oncology 5, 393-402, 2021 | 19 | 2021 |
